Lux Biosciences – a partner of Isotechnika Inc. (TSE: ISA) – has received orphan drug designation from the USFDA for its product ISA247 (LX211) for the treatment of non-infectious posterior, intermediate and pan-uveitis.
Uveitis is an autoimmune disease characterized by chronic inflammation of the eye, an often under-diagnosed and under-recognized medical condition that causes vision impairment, ocular pain, and loss of vision.
According to Ulrich Grau, President and CEO of Lux Biosciences:
"We are pleased to receive Orphan Drug designation from the FDA for LX211 (ISA247), a late-stage product in our pipeline. LX211 has the potential of establishing new treatment paradigms in these an indication of high medical need. The only drugs currently approved in uveitis are steroids."Find more details from the press release.
Comment Preview